- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00348712
Efficacy and Safety of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes
February 28, 2017 updated by: Novo Nordisk A/S
Efficacy and Safety of Inhaled Pre-prandial Human Insulin Plus Metformin Versus Rosiglitazone Plus Metformin in Type 2 Diabetes
This trial is conducted in Europe.
The aim of this research study is to compare the efficacy of adding inhaled preprandial insulin to metformin compared to adding rosiglitazone to metformin for the treatment of type 2 diabetes and to verify its safety (hypoglycaemia, pulmonary function, body weight, insulin antibodies and side effects).
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
The decision to discontinue the development of AERx® is not due to any safety concerns.
An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.
Study Type
Interventional
Enrollment (Actual)
301
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ebreichsdorf, Austria, 2483
- Novo Nordisk Investigational Site
-
Wien, Austria, 1090
- Novo Nordisk Investigational Site
-
Wien, Austria, 1030
- Novo Nordisk Investigational Site
-
-
-
-
-
Joensuu, Finland, 80130
- Novo Nordisk Investigational Site
-
Kirkkonummi, Finland, 02400
- Novo Nordisk Investigational Site
-
Turku, Finland, FI-20520
- Novo Nordisk Investigational Site
-
-
-
-
-
Corbeil Essonnes, France, 91106
- Novo Nordisk Investigational Site
-
LA ROCHELLE cedex, France, 17019
- Novo Nordisk Investigational Site
-
Mougins, France, 06250
- Novo Nordisk Investigational Site
-
NEVERS cedex, France, 58033
- Novo Nordisk Investigational Site
-
Nanterre, France, 92014
- Novo Nordisk Investigational Site
-
Narbonne, France, 11108
- Novo Nordisk Investigational Site
-
Pessac, France, 33600
- Novo Nordisk Investigational Site
-
Pointe à Pitre, France, 97159
- Novo Nordisk Investigational Site
-
Roubaix, France, 59100
- Novo Nordisk Investigational Site
-
Tours, France, 37044
- Novo Nordisk Investigational Site
-
Venissieux, France, 69200
- Novo Nordisk Investigational Site
-
-
-
-
-
Aschaffenburg, Germany, 63739
- Novo Nordisk Investigational Site
-
Augsburg, Germany, 86150
- Novo Nordisk Investigational Site
-
Bad Mergentheim, Germany, 97980
- Novo Nordisk Investigational Site
-
Berlin, Germany, 13355
- Novo Nordisk Investigational Site
-
Darmstadt, Germany, 64283
- Novo Nordisk Investigational Site
-
Dormagen, Germany, 41539
- Novo Nordisk Investigational Site
-
Dresden, Germany, 01307
- Novo Nordisk Investigational Site
-
Duisburg, Germany, 47051
- Novo Nordisk Investigational Site
-
Flörsheim, Germany, 65439
- Novo Nordisk Investigational Site
-
Frankfurt, Germany, 60590
- Novo Nordisk Investigational Site
-
Fulda, Germany, 36037
- Novo Nordisk Investigational Site
-
Genthin, Germany, 39307
- Novo Nordisk Investigational Site
-
Hermaringen, Germany, 89568
- Novo Nordisk Investigational Site
-
Kutenholz-Mulsum, Germany, 27449
- Novo Nordisk Investigational Site
-
Münster, Germany, 48145
- Novo Nordisk Investigational Site
-
Pirna, Germany, 01796
- Novo Nordisk Investigational Site
-
Schkeuditz, Germany, 04435
- Novo Nordisk Investigational Site
-
Wangen, Germany, 88239
- Novo Nordisk Investigational Site
-
Wiesbaden, Germany, 65191
- Novo Nordisk Investigational Site
-
-
-
-
-
Dublin, Ireland, DUBLIN 7
- Novo Nordisk Investigational Site
-
Dublin, Ireland, DUBLIN 8
- Novo Nordisk Investigational Site
-
Waterford, Ireland
- Novo Nordisk Investigational Site
-
-
-
-
-
Delft, Netherlands, 2625 AD
- Novo Nordisk Investigational Site
-
Den Haag, Netherlands, 2597 AX
- Novo Nordisk Investigational Site
-
Den Haag, Netherlands, 2582 LJ
- Novo Nordisk Investigational Site
-
Drachten, Netherlands, 9202 NN
- Novo Nordisk Investigational Site
-
Rijswijk, Netherlands, 2281 AK
- Novo Nordisk Investigational Site
-
Roelofarendsveen, Netherlands, 2371 RB
- Novo Nordisk Investigational Site
-
Vlodrop, Netherlands, 6063 DA
- Novo Nordisk Investigational Site
-
Zwijndrecht, Netherlands, 3331 LZ
- Novo Nordisk Investigational Site
-
-
-
-
-
Alcira, Spain, 46600
- Novo Nordisk Investigational Site
-
Barcelona, Spain, 08035
- Novo Nordisk Investigational Site
-
Gijón, Spain, 33206
- Novo Nordisk Investigational Site
-
Majadahonda, Spain, 28222
- Novo Nordisk Investigational Site
-
Palma de Mallorca, Spain, 07010
- Novo Nordisk Investigational Site
-
Partida de Bacarot, Spain, 03114
- Novo Nordisk Investigational Site
-
Pontevedra, Spain, 36071
- Novo Nordisk Investigational Site
-
Reus, Spain, 43201
- Novo Nordisk Investigational Site
-
San Juan, Spain, 03550
- Novo Nordisk Investigational Site
-
Sevilla, Spain, 41009
- Novo Nordisk Investigational Site
-
-
-
-
-
Interlaken-Unterseen, Switzerland, 3800
- Novo Nordisk Investigational Site
-
Olten, Switzerland, 4600
- Novo Nordisk Investigational Site
-
Zürich, Switzerland, 8032
- Novo Nordisk Investigational Site
-
-
-
-
-
Aberdeen, United Kingdom, AB25 1LD
- Novo Nordisk Investigational Site
-
Bath, United Kingdom, BA1 2SR
- Novo Nordisk Investigational Site
-
Belfast, United Kingdom, BT12 6BA
- Novo Nordisk Investigational Site
-
Birmingham, United Kingdom, B9 5SS
- Novo Nordisk Investigational Site
-
Bradford-on-Avon, United Kingdom, BA15 1DQ
- Novo Nordisk Investigational Site
-
Guildford, United Kingdom, GU2 7XX
- Novo Nordisk Investigational Site
-
Hull, United Kingdom, HU3 2JZ
- Novo Nordisk Investigational Site
-
Northampton, United Kingdom, NN1 5BD
- Novo Nordisk Investigational Site
-
Salford, United Kingdom, M6 8HD
- Novo Nordisk Investigational Site
-
Swansea, United Kingdom, SA6 6NL
- Novo Nordisk Investigational Site
-
Trowbridge, United Kingdom, BA14 8QA
- Novo Nordisk Investigational Site
-
Trowbridge, United Kingdom, BA14 9AR
- Novo Nordisk Investigational Site
-
Wirral, Merseyside, United Kingdom, CH63 4JY
- Novo Nordisk Investigational Site
-
York, United Kingdom, YO3 7HE
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Type 2 diabetes
- Treated with OAD(s) for more than or equal to 2 months
- Body mass index of (BMI) less than or equal to 40.0 kg/m2
- HbA1c greater than or equal to 7.5% and less than or equal to 11.0 % for subjects in OAD monotherapy and HbA1c greater than or equal to 7.0% and less than or equal to 10.0 % for subjects on OAD combination therapy
Exclusion Criteria:
- Recurrent major hypoglycaemia
- Current smoking or smoking within the last 6 months
- Impaired hepatic or renal function
- Cardiac disorders
- Uncontrolled hypertension
- Proliferative retinopathy or maculopathy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: A
|
Treat-to-target dose titration scheme, inhalation.
Other Names:
Tablets, 2000 mg/day.
|
Active Comparator: B
|
Tablets, 2000 mg/day.
Tablets, 4 mg once or twice daily.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Treatment difference in HbA1c
Time Frame: After 26 weeks
|
After 26 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events
Time Frame: For the duration of the trial
|
For the duration of the trial
|
Body weight
Time Frame: For the duration of the trial
|
For the duration of the trial
|
Lung function
Time Frame: For the duration of the trial
|
For the duration of the trial
|
Blood glucose
Time Frame: For the duration of the trial
|
For the duration of the trial
|
Hypoglycaemia
Time Frame: For the duration of the trial
|
For the duration of the trial
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 30, 2006
Primary Completion (Actual)
March 5, 2008
Study Completion (Actual)
March 5, 2008
Study Registration Dates
First Submitted
July 5, 2006
First Submitted That Met QC Criteria
July 5, 2006
First Posted (Estimate)
July 6, 2006
Study Record Updates
Last Update Posted (Actual)
March 1, 2017
Last Update Submitted That Met QC Criteria
February 28, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN1998-1390
- 2006-000796-15 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
Clinical Trials on inhaled human insulin
-
PfizerTerminatedDiabetes MellitusUnited States
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1Austria
-
PfizerCompletedDiabetes Mellitus, Type 1United States, Canada
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1Australia
-
PfizerCompletedDiabetes Mellitus, Type 1United States, Canada
-
PfizerSanofi; Nektar TherapeuticsCompletedDiabetes Mellitus, Type 2United States, Canada
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1Denmark
-
Novo Nordisk A/STerminatedDiabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1 | Chronic Obstructive Pulmonary DiseaseSlovakia, Argentina, India, Turkey, Romania, Taiwan, Thailand
-
PfizerTerminatedDiabetes Mellitus, Type 2Singapore, Hong Kong, Philippines, Pakistan
-
PfizerCompletedDiabetes Mellitus, Type 2United States, Canada